[go: up one dir, main page]

PE20020227A1 - TEST METHODS FOR IDENTIFYING COMPOUNDS THAT MAY PROTECT LAYERED FLAKY EPITHELIUM AGAINST HARM FROM HARMFUL SUBSTANCES - Google Patents

TEST METHODS FOR IDENTIFYING COMPOUNDS THAT MAY PROTECT LAYERED FLAKY EPITHELIUM AGAINST HARM FROM HARMFUL SUBSTANCES

Info

Publication number
PE20020227A1
PE20020227A1 PE2001000758A PE2001000758A PE20020227A1 PE 20020227 A1 PE20020227 A1 PE 20020227A1 PE 2001000758 A PE2001000758 A PE 2001000758A PE 2001000758 A PE2001000758 A PE 2001000758A PE 20020227 A1 PE20020227 A1 PE 20020227A1
Authority
PE
Peru
Prior art keywords
polypeptide
compound
epithelium
protect
seq
Prior art date
Application number
PE2001000758A
Other languages
Spanish (es)
Inventor
Nelia A Tobey
Roy C Orlando
Original Assignee
Univ Tulane
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tulane filed Critical Univ Tulane
Publication of PE20020227A1 publication Critical patent/PE20020227A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

SE REFIERE A METODOS DE ENSAYO PARA MONITOREAR O IDENTIFICAR LOS COMPUESTOS QUE SE USAN EN EL TRATAMIENTO DE LA ENFERMEDAD DE REFLUJO GASTROESOFAGICO QUE INCLUYEN DETERMINAR EL NIVEL DE UNA INTERACCION ENTRE EL COMPUESTO DE PRUEBA Y UNA SECUENCIA DE POLIPEPTIDOS. EL METODO DE ENSAYO PARA PROTEGER EL EPITELIO ESCAMOSO ESTRATIFICADO COMPRENDE: a) PONER EN CONTACTO UN POLIPIPEPTIDO CON UN COMPUESTO DONDE EL POLIPEPTIDO ES UNA PORCION EXTRACELULAR DE UNA CADHERINA O UNA SECUENCIA PEPTIDICA QUE TIENE AL MENOS EL 13% DE LA SECUENCIA DESCRITA DENTRO DEL DOMINIO EXTRACELULAR DE LA SEC ID No 1 O AL MENOS 5 RESIDUOS DEL DOMINO EXTRACELULAR DE LA SEC ID No 6-21, SEC ID No 22-25, ENTRE OTROS; b) DETERMINAR SI EL COMPUESTO SE UNE AL POLIPEPTIDO EN DONDE LA UNION INDICA QUE EL COMPUESTO PUEDE PROTEGER EL EPITELIO DANOS PRODUCIDOS POR UNA SUSTANCIA NOCIVA. EL METODO COMPRENDE ADEMAS COMPARAR LA UNION DEL COMPUESTO AL POLIPEPTIDO CON LA UNION DEL AGENTE CITOPROTECTOR AL POLIPEPTIDO DONDE EL AGENTE CITOPROTECTOR SE SELECCIONA DE ESTERES DE SULFATO Y SULFONATOS. EL METODO TAMBIEN COMPRENDE: i) UNIR UNA MUESTRA DE TEJIDO EPITELIAL ESCAMOSO ESTRATIFICADO CON EL COMPUESTO; ii) UNIR LA MUESTRA CON UNA SUSTANCIA NOCIVA COMO ACIDOS GASTRICOS, HCl, N-ACETILCISTEINA, PEPSINA Y iii) DETERMINAR SI EL EPITELIO HA SUFRIDO DANOSREFERS TO TEST METHODS FOR MONITORING OR IDENTIFYING THE COMPOUNDS USED IN THE TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE INCLUDING DETERMINING THE LEVEL OF AN INTERACTION BETWEEN THE TEST COMPOUND AND A POLYPEPTIDE SEQUENCE. THE TEST METHOD TO PROTECT STRATIFIED SCAMOUS EPITHELIUM INCLUDES: a) CONTACTING A POLYPEPTIDE WITH A COMPOUND WHERE THE POLYPEPTIDE IS AN EXTRACELLULAR PORTION OF A CADHERIN OR A PEPTIDIC SEQUENCE OF THE 13% DOMAIN DESCRIBE THAT HAS AT LEAST 13% OF THE DOMAIN OF DOWNLOAD. EXTRACELLULAR OF SEQ ID No 1 OR AT LEAST 5 RESIDUES OF THE EXTRACELLULAR DOMINO OF SEQ ID No 6-21, SEQ ID No 22-25, AMONG OTHERS; b) DETERMINE IF THE COMPOUND IS JOINED TO THE POLYPEPTIDE WHERE THE JOINT INDICATES THAT THE COMPOUND CAN PROTECT THE EPITHELIUM DAMAGES PRODUCED BY A HARMFUL SUBSTANCE. THE METHOD ALSO INCLUDES COMPARING THE BINDING OF THE COMPOUND TO THE POLYPEPTIDE WITH THE BINDING OF THE CYTOPROTECTOR AGENT TO THE POLYPEPTIDE WHERE THE CYTOPROTECTOR AGENT IS SELECTED FROM SULPHATE ESTERS AND SULPHONATES. THE METHOD ALSO INCLUDES: i) JOINING A SAMPLE OF FLAKY EPITHELIAL TISSUE STRATIFIED WITH THE COMPOUND; ii) JOIN THE SAMPLE WITH A HARMFUL SUBSTANCE SUCH AS GASTRIC ACIDS, HCl, N-ACETYL CYSTEINE, PEPSIN AND iii) DETERMINE WHETHER THE EPITHELIUM HAS SUFFERED DAMAGE

PE2001000758A 2000-07-28 2001-07-26 TEST METHODS FOR IDENTIFYING COMPOUNDS THAT MAY PROTECT LAYERED FLAKY EPITHELIUM AGAINST HARM FROM HARMFUL SUBSTANCES PE20020227A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62619600A 2000-07-28 2000-07-28

Publications (1)

Publication Number Publication Date
PE20020227A1 true PE20020227A1 (en) 2002-04-02

Family

ID=24509364

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000758A PE20020227A1 (en) 2000-07-28 2001-07-26 TEST METHODS FOR IDENTIFYING COMPOUNDS THAT MAY PROTECT LAYERED FLAKY EPITHELIUM AGAINST HARM FROM HARMFUL SUBSTANCES

Country Status (8)

Country Link
EP (1) EP1352247B1 (en)
AR (1) AR030000A1 (en)
AT (1) ATE308049T1 (en)
AU (1) AU2001280847A1 (en)
CA (1) CA2418377A1 (en)
DE (1) DE60114460T2 (en)
PE (1) PE20020227A1 (en)
WO (1) WO2002010767A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001283062A1 (en) 2000-08-02 2002-02-13 The Johns Hopkins University Endothelial cell expression patterns
WO2007045247A2 (en) * 2005-10-19 2007-04-26 Enkam Pharmaceuticals A/S Fibroblast growth factor receptor-derived peptides
WO2010138851A2 (en) 2009-05-29 2010-12-02 The University Of North Carolina At Chapel Hill E-cadherin as a biomarker of gastroesophageal reflux disease
CN106471130A (en) * 2014-05-09 2017-03-01 杰克逊实验室 Methods of identifying compounds that alter iRhom polypeptide activity and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189056A (en) * 1989-12-19 1993-02-23 University Of North Carolina At Chapel Hill Protection of moist stratified squamous epithelia against damage from noxious luminal agents

Also Published As

Publication number Publication date
AU2001280847A1 (en) 2002-02-13
CA2418377A1 (en) 2002-02-07
ATE308049T1 (en) 2005-11-15
EP1352247A2 (en) 2003-10-15
WO2002010767A2 (en) 2002-02-07
DE60114460D1 (en) 2005-12-01
DE60114460T2 (en) 2006-07-13
WO2002010767A3 (en) 2003-07-17
EP1352247B1 (en) 2005-10-26
AR030000A1 (en) 2003-07-23

Similar Documents

Publication Publication Date Title
Barnes et al. The collagen-platelet interaction
Dieterich et al. Cross linking to tissue transglutaminase and collagen favours gliadin toxicity in coeliac disease
ATE310955T1 (en) COMPOSITIONS AND METHODS FOR DETECTING AND TREATING CHEMOKINE RECEPTOR-RELATED DISEASES
DE69937835D1 (en) ANTIBODIES FOR APOPTOSEMARKERS AND METHOD OF USE
AR057631A1 (en) COMPOSITIONS AND METHODS TO INCREASE INSULIN SENSITIVITY
ATE549624T1 (en) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF FLU
DE59903915D1 (en) METHOD FOR EARLY DIAGNOSIS OF CARCINOMAS
ES2160319T3 (en) SYNTHETIC TEST POLLUTANT.
ES2065294B1 (en) WATER-BASED FIBRIN COMPOSITIONS AND METHOD FOR PREPARING THEM.
EA200870208A1 (en) CONSTRUCTION APPROVAL ANTIBODIES
ATE483971T1 (en) NEW METHODS FOR DETECTING AND ANALYZING PROTEIN INTERACTIONS IN VIVO
DE69821246D1 (en) TEST PROCEDURE FOR COLLAGEN PEPTIDE
FI990992A0 (en) Procedure for determining the risk of peptic ulcer
EP1275733A3 (en) Assay methods for peptidase modulators
Patak et al. Effects of tachykinins on uterine smooth muscle
PE20020227A1 (en) TEST METHODS FOR IDENTIFYING COMPOUNDS THAT MAY PROTECT LAYERED FLAKY EPITHELIUM AGAINST HARM FROM HARMFUL SUBSTANCES
Walsh et al. Neuropeptide degrading enzymes in normal and inflamed human synovium
Freise et al. The alpha 2 chain of collagen type VI sequesters latent proforms of matrix-metalloproteinases and modulates their activation and activity
Zavašnik-Bergant et al. Salivary tick cystatin OmC2 targets lysosomal cathepsins S and C in human dendritic cells
ATE366420T1 (en) KIT AND METHOD FOR DETERMINATION OF PROTEIN ESM- 1
ATE466020T1 (en) NEW ISOFORM OF VASCULAR DOTHELIAL CELL GROWTH INHIBITOR (VEGI)
DE60219645D1 (en) ANTIBODIES TO METASTIN AND ITS USE IN THE DIAGNOSIS OF PREGNANCY
DE69940927D1 (en) PEPTIDE FRAGMENTS WITH CELL DEATH PREVENTIVE ACTIVITY
ATE408832T1 (en) METHOD FOR DETECTING BLOOD CELL ANTIGENS AND ANTIBODIES DIRECTED AGAINST THESE
Gokhale et al. Glycophorin A interferes in the agglutination of human erythrocytes by concanavalin A Explanation of the requirement for enzymic predigestion

Legal Events

Date Code Title Description
FA Abandonment or withdrawal